ArticleTherapeutic advances in respiratory disease
Prognostic value of serum oncomarkers for patients hospitalized with acute exacerbation of interstitial lung disease.
Article in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Clinical features and prognostic factors of hospitalized patients with acute exacerbation of interstitial lung disease secondary to dermatomyositis/polymyositis.Clinical rheumatology · 2026Article
- A Nomogram Model for Early Mortality Risk Stratification in Elderly Patients with Idiopathic Pulmonary Fibrosis: An Integrative Analysis of Serum Biomarkers and Pulmonary Function Parameters.Journal of clinical medicine · 2026Article
- Development and external validation of a clinical-genetic risk identification model for rheumatoid arthritis-associated interstitial lung disease.Frontiers in immunology · 2026Article
- Relationship between anxiety and depression, dyspnea severity, and pulmonary function in connective tissue disease-associated interstitial lung disease.World journal of psychiatry · 2025Article
- Serum CYFRA21-1 as a novel biomarker for predicting progressive pulmonary fibrosis in non-IPF interstitial lung disease, a cohort study.BMC pulmonary medicine · 2025Article
- Sivelestat sodium: a novel therapeutic agent in a mouse model of acute exacerbation pulmonary fibrosis through multiple mechanisms.Journal of thoracic disease · 2025Article
- Dynamics of serum tumor markers may indicate the progression of interstitial lung disease in Sjögren's syndrome patients: new roles for old friends.Clinical and experimental medicine · 2025Article
- Connective tissue disease-associated interstitial lung disease risk of readmission and all-cause mortality: Interpretable machine learning approach.Chronic respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDifferent types of inflammatory processes and fibrosis have been implicated in the pathogenesis of interstitial lung disease (ILD), a heterogeneous, diffuse, parenchymal lung disease. Acute exacerbation (AE) of ILD is characterized by significant respiratory deterioration and is associated with high mortality rates. Several serum oncomarkers have been used to determine the prognosis of ILD; however, the prognostic value of serum oncomarker levels in patients with AE-ILD remains unclear.
objectiveTo evaluate the prognostic value of serum oncomarker levels in patients with AE-ILD and its main subtypes.
designRetrospective study.
methodsThe serum levels of 8 oncomarkers in 281 patients hospitalized with AE-ILD at our institution between 2017 and 2022 were retrospectively reviewed. The baseline characteristics and serum oncomarker levels were compared between the survival and non-survival groups of AE-ILD and its main subtypes. Multivariate logistic regression analysis was performed to identify independent prognosis-related markers, and the best prognostic predictor was analyzed using receiver operating characteristic curve (ROC) analysis.
resultIdiopathic pulmonary fibrosis (IPF;
conclusionCYFRA21-1 may be a viable biomarker for predicting the prognosis of patients with AE-ILD, regardless of the underlying subtype of ILD. Ferritin has a prognostic value in patients with AE-ILD or AE-CTD-ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.